Paper35317606
Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis.
Zhou J and 14 others. Thyroid, 2022. Cited by 72 papers, by iCite.
Cite this record
ConductScience Library. Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis. Papers, record 35317606. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35317606
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drinking Water | Major topic |
| Non-alcoholic Fatty Liver Disease | Major topic |
| Animals | |
| Disease Models, Animal | |
| Fatty Acids | |
| Fibrosis | |
| Humans | |
| Inflammation | |
| Liver | |
| Mice | |
| Mice, Inbred C57BL | |
| Thyroid Hormones | |
| Triglycerides |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| MC_U120085815 | Medical Research Council | United Kingdom | PubMed |
Source PubMed
Cited by45
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42979067 | Gut microbiota and treatment response heterogeneity across pharmacological therapies for MASH. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42979067 | PubMed |
| 42511461 | Exercise-Induced Hepatic Mitochondrial Reprogramming Across Muscle-Gut-Thyroid Axes in MASLD/MASH. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42511461 | PubMed |
| 42460009 | Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASH. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42460009 | PubMed |
| 42437256 | Thyroid-Liver Axis: Mechanistic Insights and Clinical Implications. | Cureus | 2026 | https://conductscience.org/library/papers/42437256 | PubMed |
| 41851447 | Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management. | Nat Rev Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/41851447 | PubMed |
| 41824051 | [New ways in interdisciplinarity: internal medicine meets human genetics : When frequent conditions become rare and rare conditions become frequent]. | Inn Med (Heidelb) | 2026 | https://conductscience.org/library/papers/41824051 | PubMed |
| 41774331 | Navigating thyroid hormone signaling in liver fibrosis: mechanisms and clinical implications. | J Endocrinol Invest | 2026 | https://conductscience.org/library/papers/41774331 | PubMed |
| 41197470 | Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer. | Pharmacol Rev | 2025 | https://conductscience.org/library/papers/41197470 | PubMed |
| 41127972 | Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial. | Aliment Pharmacol Ther | 2025 | https://conductscience.org/library/papers/41127972 | PubMed |
| 41112248 | ECM remodeling in hypothyroidism-associated MAFLD: mechanisms, clinical relevance, and therapeutic targets. | Front Immunol | 2025 | https://conductscience.org/library/papers/41112248 | PubMed |
| 40906106 | Induction of Autophagy as a Therapeutic Breakthrough for NAFLD: Current Evidence and Perspectives. | Biology (Basel) | 2025 | https://conductscience.org/library/papers/40906106 | PubMed |
| 40884700 | Impact of Levothyroxine on Progression to and Complications of Cirrhosis in MASH. | Dig Dis Sci | 2025 | https://conductscience.org/library/papers/40884700 | PubMed |
| 40777891 | Resmetirom and thyroid hormone receptor-targeted treatment for metabolic dysfunction-associated steatotic liver disease (MASLD). | Portal Hypertens Cirrhosis | 2025 | https://conductscience.org/library/papers/40777891 | PubMed |
| 40564141 | Orchestration of Gut-Liver-Associated Transcription Factors in MAFLD: From Cross-Organ Interactions to Therapeutic Innovation. | Biomedicines | 2025 | https://conductscience.org/library/papers/40564141 | PubMed |
| 40419925 | Exploring the causal relationship between Hashimoto thyroiditis and metabolic-associated fatty liver disease: A Mendelian randomization study. | Medicine (Baltimore) | 2025 | https://conductscience.org/library/papers/40419925 | PubMed |
| 40242471 | Thyroid function and hepatic fibrosis/cirrhosis: a two-sample Mendelian randomization study. | Front Genet | 2025 | https://conductscience.org/library/papers/40242471 | PubMed |
| 40016726 | Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment. | Lipids Health Dis | 2025 | https://conductscience.org/library/papers/40016726 | PubMed |
| 39990180 | Association of Sensitivity to Thyroid Hormones and Non-Alcoholic Fatty Liver Disease and the Severity of Liver Fibrosis in Euthyroid Adults: A Retrospective Study. | Diabetes Metab Syndr Obes | 2025 | https://conductscience.org/library/papers/39990180 | PubMed |
| 39765829 | Ganoderma lucidum Spore Powder Alleviates Metabolic-Associated Fatty Liver Disease by Improving Lipid Accumulation and Oxidative Stress via Autophagy. | Antioxidants (Basel) | 2024 | https://conductscience.org/library/papers/39765829 | PubMed |
| 39462343 | Exosomes derived from apical papilla stem cells improve NASH by regulating fatty acid metabolism and reducing inflammation. | Mol Med | 2024 | https://conductscience.org/library/papers/39462343 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35317606
GET https://conductscience.org/api/papers/v1/35317606/cited_by?page=2